Development of a patient decision aid regarding SBRT radiation dose to peripheral tumors in the lung
Thomas Leth Fink,
Denmark
PD-0084
Abstract
Development of a patient decision aid regarding SBRT radiation dose to peripheral tumors in the lung
Authors: Thomas Leth Fink1, Charlotte Kristiansen1, Rune Slot Thing1, Torben Schjødt Hansen1, Torben Frøstrup Hansen1
1Institute of Regional Health Research, Department of Oncology, Vejle, Denmark
Show Affiliations
Hide Affiliations
Purpose or Objective
Patient
involvement is receiving increased attention from the healthcare system, decision-makers,
clinicians and patients. One way of increasing the patient involvement is
through the concept of Shared Decision Making (SDM), which is a collaborative
process allowing patients and healthcare professionals to make decisions
together taking into account the best scientific evidence as well as patients’
values, preferences, life situation, and knowledge about disease process and
prognosis.
Patient
decision aids (PtDAs) are tools designed to assist caregivers in the process of
informing patients about relevant treatment options. PtDAs contain factual and
balanced information about the options and the pertaining pros, cons and
probabilities. The tools can be digital, paper-based, videos, etc. and are
often designed to a specific situation.
We present
the process of developing a printed PtDA to assist in the choice of high (66 Gy
in 3 fractions) or lower (45 Gy in 3 fractions) dose of SBRT for a tumor in the
lung located adjacent (< 1 cm) to the thoracic wall. When treating tumors in
this location with radiation therapy, there is an increased risk of causing
chest wall pain or rib fractures in the patient. For this reason, reduction of
the dose is common at the discretion of the physician, without asking for the
patient’s preference. We want to involve the patients in this decision by using
the PtDA.
Material and Methods
The Regional Center for SDM at Vejle Hospital has developed a generic PtDA template in print, which forms the basis for our PtDA. The template consists of a frame that forms the setting for the decision that is to be made. Placed inside the frame is then different cards showing pros and cons for the different options, the timeline for the course and statistics.
Results
During the
spring of 2021, drafts for the paper cards showing the different dose levels,
the timeline and statistics on the risk of side effects and expected local
control were produced. We conducted a half-day workshop with both patients,
relatives, physicians and RTT’s in May 2021. Drafts received comments and
suggestions for improvement, statistics was altered to be easier to understand
and patient stories were collected during the day. In particular, the direct
input from patients helped improve the PtDA.
The result
of this process was the second draft, which was then subjected to an alpha-test
with four individual physicians, where the design and wording of the PtDA was
further refined.
During the process there was a tight collaboration with a consultant at the Center for SDM, who also made comments about the design before the workshop was held.
Example of card with statistics
Conclusion
The final PtDA consists of a frame and 12 sheets and will be demonstrated at the conference. The PtDA will serve as the intervention in an upcoming RCT.